Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27794126 | 0.86 | BAZ2B (0.58) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL9918752 | 0.78 | BAZ2B (0.54) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL14150292 | 0.74 | BAZ2B (0.73) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL1298188 | 0.71 | BAZ2B (0.54) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL4643847 | 0.70 | CA1 (0.58) | ALDH1A1KMT2ALMNA | |
| SCHEMBL21060871 | 0.70 | PLA2G2A (0.51) | BAZ2BBAZ2AALDH1A1 | |
| SCHEMBL4544349 | 0.69 | BAZ2B (0.62) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL21060866 | 0.69 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL162449 | 0.69 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL5202768 | 0.69 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230098872-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022204452-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20210220328-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ALMIRALL SA (ES) | 2021-07-22 | — | — | US | disclosed |
| CN-111886230-A | Pyrrole derivatives as ACC inhibitors | 阿尔米雷尔有限公司 | 2020-11-03 | — | — | CN | disclosed |
| EP-3724182-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | Almirall S.A. (ES) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019115405-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ALMIRALL, S.A. (ES) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230098872-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | BAZ2B 1257/4885BAZ2A 1306/4885ALDH1A1 1319/4885 |
| US-20210220328-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ACACA, ACACB, PCCA | BAZ2B 2995/4885BAZ2A 2954/4885ALDH1A1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.